Corindus Vascular Robotics (NYSE:CVRS) said today that its stockholders approved the adoption of a $1.1 billion merger with with Siemens (NYSE:SI).

Waltham, Mass.-based Corindus said the transaction is slated to close Oct. 29, after which Corindus will be delisted from the New York Stock Exchange, according to a news release.

Corindus stockholders are set to receive $4.28 per each share of common stock owned in cash, along with $85.60 in cash for each share of Series A convertible preferred stock.

The merger agreement was announced August 7. Nearly a month later, the U.S. Federal Trade Commission granted early termination of the statutory waiting period.

Earlier this week, Corindus moved to forestall a group of lawsuits brought over the acquisition. The announcement in August prompted six lawsuits alleging that Corindus provided incomplete and misleading financial projections and omitted key inputs for the financial analysis performed by RBC Capital Markets. Corindus denied the allegations.

Shares of CVRS stayed put while shares of SI were down -0.9% at $20.86 per share in midday trading today.